V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10458019 | 10057641 | 1.75 | 62.2 | null | 2016-04-08 | 2016-04-22 | Capecitabine + Trastuzumab | 02 | null | EVEROLIMUS | 101589724 |
| 10458219 | 10057644 | 0 | 70.5 | Palliative (P) | 2021-06-04 | 2021-06-06 | Ipilimumab | 02 | N | PEMETREXED | 100775748 |
| 10458341 | 10057645 | 1.69 | 64.3 | null | 2021-03-29 | 2021-04-13 | OXALIPLATIN + MDG + PANITUMUMAB | 02 | null | FULVESTRANT + PALBOCICLIB | 101035248 |
| 10458629 | 10057646 | 1.7 | 73 | Palliative (P) | 2019-08-12 | 2019-08-16 | ISATUXIMAB + POMALIDOMIDE | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + PERTUZUMAB + TRASTUZUMAB | 100675885 |
| 10459331 | 10057648 | 1.55 | 59.1 | Palliative (P) | null | 2021-06-10 | Erlotinib | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100769524 |
| 10459358 | 10057649 | 1.81 | null | Palliative (P) | 2018-03-13 | 2018-03-30 | null | 02 | null | NOT MATCHED | 101133889 |
| 10459636 | 10057650 | 1.68 | 46.1 | Curative (C) | 2021-08-26 | 2021-08-26 | MUK 12 TRIAL | Y | N | CTD | 101531292 |
| 10459673 | 10057651 | 1.69 | 98.35 | Palliative (P) | 2019-01-15 | 2019-09-22 | null | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100515397 |
| 10460308 | 10057656 | 1.83 | 75 | Palliative (P) | 2019-06-01 | 2019-06-20 | null | 01 | N | PERSEPHONE TRIAL | 101674381 |
| 10460339 | 10057657 | 1.7 | 82.7 | 03 | 2020-08-16 | 2020-08-29 | PLATFORM Trial | N | N | EXEMESTANE + PALBOCICLIB | 101834345 |
| 10460412 | 10057658 | 1.53 | 67.5 | null | 2022-04-27 | 2022-05-07 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | null | CYTARABINE + FLUDARABINE + IDARUBICIN | 101301221 |
| 10460666 | 10057660 | 0 | 84 | null | 2021-03-22 | 2021-03-29 | PERTUZUMAB | 02 | null | CAR-T AXICABTAGENE CILOLEUCEL + CYCLOPHOSPHAMIDE + FLUDARABINE | 101298396 |
| 10461081 | 10057663 | 1.51 | 57 | Palliative (P) | 2017-11-13 | 2017-11-15 | GEMCITABINE + NAB PACLITAXEL | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101644565 |
| 10461281 | 10057664 | 1.75 | 64 | null | 2018-12-23 | 2019-03-18 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE | 02 | null | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100530210 |
| 10461518 | 10057666 | 0 | 78 | 03 | 2021-05-20 | 2021-05-28 | BLEOMYCIN | 02 | N | CYCLOPHOSPHAMIDE + POMALIDOMIDE | 100640722 |
| 10461875 | 10057669 | 1.67 | 65 | null | 2016-08-13 | 2016-09-02 | null | 02 | null | VISMODEGIB | 101721378 |
| 10462117 | 10057670 | 1.78 | 74 | null | 2021-06-07 | 2021-07-01 | Binimetinib + Encorafenib | 02 | null | FLAIR TRIAL | 101325522 |
| 10462369 | 10057672 | 1.65 | 80.4 | null | 2019-08-01 | 2019-08-14 | Durvalumab | 02 | null | AZACITIDINE + VENETOCLAX | 100965868 |
| 10462518 | 10057673 | 1.8 | 79.7 | null | 2019-02-07 | 2019-02-26 | Brentuximab | 02 | null | PAZOPANIB | 101519421 |
| 10462633 | 10057675 | 1.82 | 0 | null | 2021-02-10 | 2021-02-10 | Sunitinib | 02 | null | IRINOTECAN | 100657905 |
| 10462696 | 10057676 | 1.48 | 103 | null | 2018-10-24 | 2019-05-07 | Topotecan (oral) | 02 | null | OXALIPLATIN + RALTITREXED | 101412645 |
| 10462918 | 10057679 | 0 | 56 | 03 | 2012-04-21 | 2018-08-16 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | BCG | 100188063 |
| 10463139 | 10057681 | 1.58 | 81 | Palliative (P) | null | 2017-11-19 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 02 | N | OBINUTUZUMAB | 100821151 |
| 10463388 | 10057684 | 1.7 | 75 | Disease modification (D) | 2019-08-07 | 2019-08-07 | VEDex | 02 | N | VISMODEGIB | 100668308 |
| 10463581 | 10057686 | 1.83 | 92.7 | null | 2018-08-17 | 2018-08-17 | Carboplatin + Pembrolizumab + Pemetrexed | 02 | null | CYTARABINE + RITUXIMAB | 101189011 |
| 10463603 | 10057687 | 1.69 | 0 | Curative (C) | 2019-02-05 | 2019-02-05 | Brentuximab | 02 | N | LENALIDOMIDE + RITUXIMAB | 101362817 |
| 10463797 | 10057689 | 1.54 | 85.6 | Palliative (P) | 2017-04-07 | 2017-04-07 | null | 02 | N | ABEMACICLIB + FULVESTRANT | 100361329 |
| 10464201 | 10057690 | 1.66 | 72.2 | null | 2019-01-10 | 2020-02-19 | Ipilimumab | null | null | MATRIX LYMPHOMA TRIAL | 100004424 |
| 10464465 | 10057692 | 1.65 | 70.8 | Palliative (P) | 2014-04-15 | 2014-06-06 | EVEROLIMUS | 02 | N | GEMTUZUMAB OZOGAMICIN | 100103226 |
| 10464609 | 10057694 | 0 | 52 | 03 | 2018-11-09 | 2018-11-10 | null | 02 | N | CETUXIMAB + IRINOTECAN + MDG | 101842635 |
| 10464820 | 10057696 | 1.83 | 0 | Palliative (P) | 2019-02-19 | 2019-03-06 | Fluorouracil+Mitomycin+RT (Bladder) | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL + TRASTUZUMAB | 101095479 |
| 10464960 | 10057698 | 1.69 | null | Palliative (P) | 2021-01-21 | 2021-01-21 | GEMCITABINE + NAB PACLITAXEL | 02 | N | ISATUXIMAB + POMALIDOMIDE | 101572022 |
| 10465111 | 10057700 | 1.82 | 62.6 | Palliative (P) | 2019-10-30 | 2019-10-30 | Sorafenib | 02 | N | LIPOSOMAL DOXORUBICIN | 100758195 |
| 10465254 | 10057701 | 0 | 0 | Neo-adjuvant (N) | 2019-03-11 | 2019-03-15 | null | 02 | N | GEMCARBO | 101770504 |
| 10465263 | 10057702 | 1.64 | 59.4 | null | 2017-09-13 | 2017-09-19 | CYCLOPHOSPHAMIDE + POMALIDOMIDE | 99 | null | CARBOPLATIN + DOCETAXEL | 100059599 |
| 10465351 | 10057703 | 0 | 72 | null | 2020-01-03 | 2020-01-04 | Rucaparib | 02 | null | CTD | 100437259 |
| 10465381 | 10057704 | null | null | null | 2016-01-09 | 2016-03-11 | CHOP - 21 days | 02 | null | BEVACIZUMAB + CARBO + PACLITAXEL | 100096383 |
| 10465398 | 10057705 | 1.67 | 84.8 | Palliative (P) | 2018-11-16 | 2018-11-30 | Durvalumab | 02 | null | ISATUXIMAB + POMALIDOMIDE | 101150734 |
| 10465735 | 10057708 | 1.76 | 85.8 | Curative (C) | null | 2020-07-28 | Eribulin | 02 | N | TEPOTINIB | 101320526 |
| 10465757 | 10057709 | null | 120.5 | Palliative (P) | 2018-12-03 | 2018-12-08 | AXITINIB | 02 | N | OXALIPLATIN + MDG | 101283390 |
| 10465806 | 10057710 | 1.84 | 88 | Palliative (P) | 2019-09-12 | 2019-09-30 | PEMBROLIZUMAB + PEMETREXED | 02 | null | CAPECITABINE + CARBOPLATIN | 100242858 |
| 10465839 | 10057712 | null | 108 | Adjuvant (A) | 2020-05-17 | 2020-05-19 | FLAIR trial | 02 | N | THALIDOMIDE | 100496246 |
| 10466000 | 10057714 | 1.67 | 80.8 | Curative (C) | 2019-11-08 | 2019-12-15 | CARFILZOMIB + Dexamethasone | 02 | N | ISATUXIMAB + POMALIDOMIDE | 101755483 |
| 10466066 | 10057715 | 1.85 | 94.2 | null | 2017-12-21 | 2017-12-21 | LIPOSOMAL DAUNORUBICIN + CYTARABINE (Vyxeos) | 02 | null | BINIMETINIB + ENCORAFENIB | 101073213 |
| 10466125 | 10057716 | 1.7 | 109 | Palliative (P) | 2017-06-04 | 2018-12-21 | AXITINIB | 02 | N | FLAIR TRIAL | 100035444 |
| 10466178 | 10057717 | null | 55.6 | null | 2018-03-12 | 2018-03-19 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 02 | null | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 101557693 |
| 10466233 | 10057718 | 1.7 | 116.4 | null | 2020-01-28 | 2020-02-18 | STAR TRIAL | 02 | null | DOCETAXEL + TRASTUZUMAB | 101386523 |
| 10466432 | 10057720 | null | 63 | null | null | 2016-10-15 | OSIMERTINIB | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 101256506 |
| 10466480 | 10057721 | null | 96 | null | 2017-05-24 | 2017-06-09 | Fulvestrant + Ribociclib | 99 | null | TOPOTECAN | 101199601 |
| 10466573 | 10057722 | 1.55 | 56.4 | Palliative (P) | 2017-12-25 | 2018-01-15 | ABEMACICLIB + FULVESTRANT | 02 | N | BEXAROTENE | 100469967 |